Intravenous-to-Subcutaneous (IV-to-SC) Drug Migration, 2019-2024 Research Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Intravenous-to-Subcutaneous Drug Repositioning" report has been added to ResearchAndMarkets.com's offering.

As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection.

While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration path is now becoming a significant pathway in the life cycle of many parenteral drugs. A number of technology approaches are currently being employed to accomplish this migration. By pursuing IV-to-SC strategies, drug owners are finding they can achieve a number of competitive advantages.

Intravenous-to-Subcutaneous Drug Markets - What You Will Learn

• What intravenous drugs have been strategically re-engineered for subcutaneous administration, what are the technologies being used, and what is their current market status?
• What are the therapeutic markets that are viewed as having the greatest potential for IV-to-SC migration?
• What are the major factors driving intravenous-to-subcutaneous drug re-engineering?
• How are intravenous-to-subcutaneous drugs currently aligned with drug classes and therapeutic markets?
• What intravenous drugs are currently being developed for eventual release as subcutaneously administered drugs, and what is their current status?
• What is the market impact of IV-to-SC drug migration? What will it be in 2024?
• Who are the significant players in this segment? What are their strategies? Who are their alliance partners?

Key Topics Covered:

1. Executive Summary
2. Intravenous-to-Subcutaneous Market Dynamics
3. IV-to-SC Repositioning - The Market Opportunity
4. The Addressable Market
5. Market Drivers
6. Patient-centric Therapeutics
7. Device Evolution and Enablement
8. Patent Life and IP Strategies
9. Managed Care and Healthcare Economics
10. Product Development Factors
11. Lyophilized Drugs/Reconstitution
12. Human Engineering/Ergonomics
13. Competitive Landscape
14. Risk Factors
15. Intravenous-to-Subcutaneous Technology
16. Drug Formulation
17. Injection Site Modification
18. Device Innovation
19. IV-to-SC Repositioning - Product Segment Analysis
20. Device Analysis
21. Wearable SC Infusors
22. Wearable SC Injectors
23. Drug Product Analysis
24. Antibiotics
25. Blood Factors
26. CSL Behring (Enable Injections)
27. Diuretics
28. Antiemetics
29. Hematopoietics
30. Immune Factors
31. Immunoglobulin G (Hyqvia/Baxalta)
32. Immunotherapeutics
33. Vasodilators
34. Prostacyclin (SteadyMed Therapeutics)
35. Remodulin (United Therapeutics)
36. IV-to-SC - Therapeutic Sector Analysis
37. Cardiology
38. Edema
39. Pulmonary Arterial Hypertension
40. Hematology
41. Blood Factors
42. Oncology
43. Market Factors
44. Regulatory Issues
45. Collaborations and Alliances
46. Emerging Technologies
47. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/37ggg6/intravenoustosub?w=4